-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals to read and refer to the opening video.
The first row from left to right: Professor Liang Jun, Professor Lu You, Professor Ma Jun, Professor Zhou Jian, and Professor Chen Minshan.
Second row from left to right: Professor Li Guoxin, Professor Xu Ruihua, Prof.
Yu Jinming, Prof.
Qin Shukui, Prof.
Li Jin, and Prof.
Sun Huichuan The third row from left to right: Prof.
Dai Guanghai, Prof.
Wang Zhehai, Prof.
Zhou Caicun, Prof.
Li Baosheng, Prof.
Hu Yi, and Prof.
Zhang Li for the in-depth implementation of the "14th Five-Year Plan" In accordance with the spirit of the National Clinical Specialty Capacity Building Plan, the Action Plan for Improving the Quality of Tumor Diagnosis and Treatment, and the National Health and Health Commission's Capacity Building and Continuing Education Center launched the "Tumor Immunity Trust China" training program to improve tumor immunity standardized diagnosis and treatment capabilities
.
The project is supported and guided by the National Health and Health Commission's Capacity Building and Continuing Education Oncology Expert Committee, and is supported by Innovent Biopharmaceuticals.
Construction related work
.
On February 12, domestic oncology experts gathered in the cloud to witness the wonderful moment of the launch of this project, and talked about the new progress of tumor immunotherapy and shared cutting-edge views in the academic exchange session
.
Foreword: A new chapter is created by the fire of trust.
Director Yang Aiping of the National Health Commission's Capacity Building and Continuing Education Center pointed out that strengthening the capacity building of county-level oncology specialists is to thoroughly implement the national strategy, effectively promote the high-quality development of public hospitals, and effectively improve primary medical care.
It is an important measure to promote the effective implementation of the hierarchical diagnosis and treatment system
.
It is hoped that in the process of project implementation, we will continue to adhere to demand orientation, adhere to model innovation, and continue to empower the grassroots through digital continuing education, so as to ensure the health and well-being of the grassroots
.
The academic content of the conference kicked off with speeches by Academician Yu Jinming of Shandong Cancer Hospital and Prof.
Qin Shukui from Cancer Center of Nanjing Jinling Hospital.
They pointed out that the current incidence and mortality of cancer in China are still on the rise, and new cases will be added every minute in our country.
7 cancer patients, and 5 patients will die due to cancer
.
We have the largest tumor patient population in the world, which is characterized by high morbidity, high mortality and heavy disease burden, which means that the situation of tumor diagnosis and treatment in China is quite severe
.
In order to effectively strengthen the construction of tumor specialist talent teams in small and medium-sized cities, improve medical service capabilities, and improve the standardization level of tumor immunotherapy drugs, implement the "Healthy China 2030" Planning Outline, "Tumor Immunity Trust China" tumor immunity standardized diagnosis and treatment capacity improvement training The project started just in time
.
As medical workers, Academician Yu Jinming and Professor Qin Shukui expressed the hope that all medical colleagues will work together to explore the path of cancer immunotherapy in China
.
It is hoped that the majority of colleagues will integrate academic resources, focus on standardized treatment, strengthen cooperation and exchanges, and make progress together, so as to improve the level of tumor diagnosis and treatment in basic hospitals and benefit more tumor patients
.
At this conference, a number of top domestic tumor immunotherapy experts have gathered.
They will combine their own diagnosis and treatment experience and the latest academic progress to conduct academic sharing of tumor immunotherapy.
income
.
We look forward to the development of the "Tumor Immunity Xinhuo China" training program to improve the standardized diagnosis and treatment capabilities of tumor immunity in the future, which can promote the overall improvement of the level of tumor immunotherapy in China
.
Director Yang Aiping, Academician Yu Jinming, and Academician Qin Shukui, then, professors from Beijing, Shanghai, Guangzhou, Chengdu, Jinan, oncology treatment expert group delivered speeches and greetings to the project launch conference in the cloud.
He fully affirmed the significance of the training program for improving the ability of standardized diagnosis and treatment of immunization, and expressed his full support for the advancement of the program
.
After the preface, the exciting project launching ceremony was officially opened.
Director Yang Aiping, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Xu Ruihua of Sun Yat-sen University Cancer Center, Professor Li Jin of Tongji University Affiliated Oriental Hospital, Fudan University Affiliated Zhongshan Professor Zhou Jian of the Hospital, Professor Zhou Caicun of Shanghai Pulmonary Hospital Affiliated to Tongji University, Professor Liang Jun of Peking University International Hospital, Professor Li Baosheng of Shandong Cancer Hospital, Professor Li Guoxin of Nanfang Hospital of Southern Medical University, Professor Chen Minshan of Sun Yat-sen University Cancer Center, Shandong Province Professor Wang Zhehai of Cancer Hospital, Professor Hu Yi of Chinese People's Liberation Army General Hospital, and Professor Dai Guanghai of Chinese People's Liberation Army General Hospital jointly lit the torch of Xinhuo China, announcing the official launch of the "Tumor Immunity Xinhuo China" training program to improve the standardized diagnosis and treatment capabilities of tumor immunity! The first chapter of the project launching ceremony: First-line victory, standardization first and first-line victory - new standard of immunotherapy for advanced non-small cell lung cancer Moderator: Professor Lu Yu, West China Hospital, Sichuan University Speaker: Professor Zhou Caicun, Shanghai Pulmonary Hospital, Tongji University, advanced non-small cell lung cancer Lung cancer (NSCLC) treatment has entered the era of immunity, and immunotherapy combined with chemotherapy has become the new standard for first-line treatment of advanced NSCLC
.
Clinical research data confirms that, compared with first-line chemotherapy and then receiving PD-1 inhibitor treatment, first-line use of PD-1 inhibitor can significantly prolong the overall survival of patients and benefit patients more
.
In 2021, the official journal of the International Association for the Study of Lung Cancer (JTO) published a META analysis evaluating the efficacy and safety of first-line immunotherapy for NSCLC, evaluating the seven most important PD-1/PD-L1 inhibitors at home and abroad, and It corresponds to the 16 most representative Phase III clinical studies of advanced first-line immune combination regimens in the treatment of NSCLC
.
The results showed that compared with standard chemotherapy, immunocombination therapy can achieve more overall survival (OS) and progression-free survival (PFS) benefits
.
Professor Lu U, Professor Zhou Caicun, by the end of 2021, more PD-1 inhibitors and indications will be included in the medical insurance, and the availability of drugs for the treatment of advanced first-line NSCLC has been further improved.
Reduce patient burden
.
Unique - Immunotherapy reshapes the new pattern of first-line treatment of advanced liver cancer Moderator: Professor Zhou Jian, Zhongshan Hospital Affiliated to Fudan University Speaker: Professor Sun Huichuan, Zhongshan Hospital Affiliated to Fudan University Although TKIs are effective, the survival benefit is limited and a breakthrough is urgently needed
.
Compared with sorafenib alone, immunotherapy such as sintilimab + bevacizumab (double-dose regimen) in the first-line treatment of liver cancer significantly reduced the risk of death by 43% and the risk of disease progression by 44%.
The survival benefit of patients is significant, and the Meta-analysis shows that the combination of Shuangda may become the best clinical solution for the first-line treatment of advanced liver cancer
.
The first-line treatment of liver cancer with Shuangda regimen has obtained the 2022 edition of the National Health Commission's "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer", the 2021 edition of "CSCO Guidelines for Clinical Application of Immune Checkpoint Inhibitors", and the 2021 edition of CACA's "Expert Consensus on Multidisciplinary Comprehensive Treatment of Liver Cancer in China", etc.
The authoritative guide unanimously recommends
.
In addition, phase III clinical studies of first-line treatment based on immunotherapy are in full swing, such as sintilimab combined with anti-CTLA-4 monoclonal antibody (IBI310).
Treatment options, reshape the new pattern of first-line treatment of advanced liver cancer, and bring more benefits to patients
.
Professor Zhou Jian, Professor Sun Huichuan, China-Immunotherapy opens a new chapter in the first-line treatment of advanced gastric cancer Moderator: Professor Li Jin, Dongfang Hospital Affiliated to Tongji University Speaker: Professor Dai Guanghai, General Hospital of the Chinese People's Liberation Army , the prognosis is poor, chemotherapy as a standard treatment has faced a bottleneck in efficacy, and targeted therapy can benefit a limited population, and the current status of advanced gastric cancer treatment is not optimistic
.
The emergence of immunotherapy has brought new hope to patients with gastric cancer.
Several studies have confirmed that immunotherapy has brought benefits to patients with advanced gastric cancer, making it recommended by guidelines
.
Immunotherapy and chemotherapy have a synergistic effect, and combined therapy has repeatedly achieved good results in the exploration of advanced metastatic gastric cancer, breaking the pattern of traditional treatment
.
ORIENT-16 is the first phase III clinical study in China to demonstrate that first-line immunotherapy significantly prolongs the overall survival of patients with advanced gastric cancer.
This study provides strong evidence for the combination of immunotherapy and chemotherapy for advanced gastric cancer in China, and also provides clinical evidence for the combination of sintilimab and chemotherapy.
This first-line treatment option
.
In conclusion, immunotherapy for advanced gastric cancer can be expected in the future, and the combination of biomarker-oriented and immunotherapy will further prolong the OS of patients and promote the development of personalized immunotherapy for gastric cancer
.
Prof.
Li Jin, Prof.
Dai Guanghai Chapter 2: Talking about the truth and sharing the future irAE management experience Moderator: Prof.
Liang Jun, Peking University International Hospital Speaker: Prof.
Zhang Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital ) has a wide spectrum of toxicity, but the overall incidence is low.
Grade 3-4 irAEs are rare, and the occurrence of irAEs is time-regular and reversible
.
In the process of immunotherapy, the diagnosis of irAE is more based on experience and requires the joint participation of a multidisciplinary team to achieve early diagnosis and early treatment
.
It is worth noting that irAEs may occur repeatedly and late, so during the entire immunotherapy process and subsequent follow-up, clinicians should remain vigilant about irAEs and make careful assessments
.
Professor Liang Jun, Professor Zhang Dajia Talks: Current Situation and Prospects of Standardized Diagnosis and Treatment of Tumor Immunity Moderator: Professor Qin Shukui, Nanjing Jinling Hospital Guest: Professor Xu Ruihua, Sun Yat-sen University Cancer Center Four experts from the General Hospital, Professor Hu Yi, shared their insights from different latitudes of standardized diagnosis and treatment of tumor immunity, and made a prospect of the training program to improve the ability of standardized diagnosis and treatment of tumor immunity in "Tumor Immunity Trust China"
.
Experts pointed out that despite the development of science and technology, the survival rate of cancer patients has been continuously improved
.
However, China has a vast territory and abundant resources, and the level of diagnosis and treatment varies among different regions and hospitals
.
At present, the country is vigorously promoting the implementation of the hierarchical diagnosis and treatment policy, which has achieved initial results, and we are also pursuing the maximum development under the policy advantages
.
Through the implementation of training programs such as "Tumor Immunity Xinhuo China" standardized diagnosis and treatment capacity improvement training programs for tumors, higher-level hospitals and primary hospitals can be linked, so as to formulate appropriate treatment strategies for patients in primary hospitals, so that more patients in primary hospitals can achieve "tumor immunity".
chronic disease"
.
Da Jia Tan: The current situation and prospect of standardized diagnosis and treatment of tumor immunity The conference concluded at the end of the conference.
Professor Qin Shukui said in his summary that the conference presented a wonderful academic feast in the form of online live broadcast, and successfully completed the various This agenda has witnessed the launch of the "Tumor Immunity Trust China" training program to improve the standardized diagnosis and treatment capabilities of tumor immunity
.
Sincere thanks to all the academic sharing experts and the behind-the-scenes workers, who have given us a better understanding of the standardized treatment of tumor immunity, and can better guide the immunotherapy drugs for oncology specialists in small and medium-sized cities
.
In the future, I hope that everyone will work together to create a bright future for China's tumor immunotherapy
.
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
The first row from left to right: Professor Liang Jun, Professor Lu You, Professor Ma Jun, Professor Zhou Jian, and Professor Chen Minshan.
Second row from left to right: Professor Li Guoxin, Professor Xu Ruihua, Prof.
Yu Jinming, Prof.
Qin Shukui, Prof.
Li Jin, and Prof.
Sun Huichuan The third row from left to right: Prof.
Dai Guanghai, Prof.
Wang Zhehai, Prof.
Zhou Caicun, Prof.
Li Baosheng, Prof.
Hu Yi, and Prof.
Zhang Li for the in-depth implementation of the "14th Five-Year Plan" In accordance with the spirit of the National Clinical Specialty Capacity Building Plan, the Action Plan for Improving the Quality of Tumor Diagnosis and Treatment, and the National Health and Health Commission's Capacity Building and Continuing Education Center launched the "Tumor Immunity Trust China" training program to improve tumor immunity standardized diagnosis and treatment capabilities
.
The project is supported and guided by the National Health and Health Commission's Capacity Building and Continuing Education Oncology Expert Committee, and is supported by Innovent Biopharmaceuticals.
Construction related work
.
On February 12, domestic oncology experts gathered in the cloud to witness the wonderful moment of the launch of this project, and talked about the new progress of tumor immunotherapy and shared cutting-edge views in the academic exchange session
.
Foreword: A new chapter is created by the fire of trust.
Director Yang Aiping of the National Health Commission's Capacity Building and Continuing Education Center pointed out that strengthening the capacity building of county-level oncology specialists is to thoroughly implement the national strategy, effectively promote the high-quality development of public hospitals, and effectively improve primary medical care.
It is an important measure to promote the effective implementation of the hierarchical diagnosis and treatment system
.
It is hoped that in the process of project implementation, we will continue to adhere to demand orientation, adhere to model innovation, and continue to empower the grassroots through digital continuing education, so as to ensure the health and well-being of the grassroots
.
The academic content of the conference kicked off with speeches by Academician Yu Jinming of Shandong Cancer Hospital and Prof.
Qin Shukui from Cancer Center of Nanjing Jinling Hospital.
They pointed out that the current incidence and mortality of cancer in China are still on the rise, and new cases will be added every minute in our country.
7 cancer patients, and 5 patients will die due to cancer
.
We have the largest tumor patient population in the world, which is characterized by high morbidity, high mortality and heavy disease burden, which means that the situation of tumor diagnosis and treatment in China is quite severe
.
In order to effectively strengthen the construction of tumor specialist talent teams in small and medium-sized cities, improve medical service capabilities, and improve the standardization level of tumor immunotherapy drugs, implement the "Healthy China 2030" Planning Outline, "Tumor Immunity Trust China" tumor immunity standardized diagnosis and treatment capacity improvement training The project started just in time
.
As medical workers, Academician Yu Jinming and Professor Qin Shukui expressed the hope that all medical colleagues will work together to explore the path of cancer immunotherapy in China
.
It is hoped that the majority of colleagues will integrate academic resources, focus on standardized treatment, strengthen cooperation and exchanges, and make progress together, so as to improve the level of tumor diagnosis and treatment in basic hospitals and benefit more tumor patients
.
At this conference, a number of top domestic tumor immunotherapy experts have gathered.
They will combine their own diagnosis and treatment experience and the latest academic progress to conduct academic sharing of tumor immunotherapy.
income
.
We look forward to the development of the "Tumor Immunity Xinhuo China" training program to improve the standardized diagnosis and treatment capabilities of tumor immunity in the future, which can promote the overall improvement of the level of tumor immunotherapy in China
.
Director Yang Aiping, Academician Yu Jinming, and Academician Qin Shukui, then, professors from Beijing, Shanghai, Guangzhou, Chengdu, Jinan, oncology treatment expert group delivered speeches and greetings to the project launch conference in the cloud.
He fully affirmed the significance of the training program for improving the ability of standardized diagnosis and treatment of immunization, and expressed his full support for the advancement of the program
.
After the preface, the exciting project launching ceremony was officially opened.
Director Yang Aiping, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Xu Ruihua of Sun Yat-sen University Cancer Center, Professor Li Jin of Tongji University Affiliated Oriental Hospital, Fudan University Affiliated Zhongshan Professor Zhou Jian of the Hospital, Professor Zhou Caicun of Shanghai Pulmonary Hospital Affiliated to Tongji University, Professor Liang Jun of Peking University International Hospital, Professor Li Baosheng of Shandong Cancer Hospital, Professor Li Guoxin of Nanfang Hospital of Southern Medical University, Professor Chen Minshan of Sun Yat-sen University Cancer Center, Shandong Province Professor Wang Zhehai of Cancer Hospital, Professor Hu Yi of Chinese People's Liberation Army General Hospital, and Professor Dai Guanghai of Chinese People's Liberation Army General Hospital jointly lit the torch of Xinhuo China, announcing the official launch of the "Tumor Immunity Xinhuo China" training program to improve the standardized diagnosis and treatment capabilities of tumor immunity! The first chapter of the project launching ceremony: First-line victory, standardization first and first-line victory - new standard of immunotherapy for advanced non-small cell lung cancer Moderator: Professor Lu Yu, West China Hospital, Sichuan University Speaker: Professor Zhou Caicun, Shanghai Pulmonary Hospital, Tongji University, advanced non-small cell lung cancer Lung cancer (NSCLC) treatment has entered the era of immunity, and immunotherapy combined with chemotherapy has become the new standard for first-line treatment of advanced NSCLC
.
Clinical research data confirms that, compared with first-line chemotherapy and then receiving PD-1 inhibitor treatment, first-line use of PD-1 inhibitor can significantly prolong the overall survival of patients and benefit patients more
.
In 2021, the official journal of the International Association for the Study of Lung Cancer (JTO) published a META analysis evaluating the efficacy and safety of first-line immunotherapy for NSCLC, evaluating the seven most important PD-1/PD-L1 inhibitors at home and abroad, and It corresponds to the 16 most representative Phase III clinical studies of advanced first-line immune combination regimens in the treatment of NSCLC
.
The results showed that compared with standard chemotherapy, immunocombination therapy can achieve more overall survival (OS) and progression-free survival (PFS) benefits
.
Professor Lu U, Professor Zhou Caicun, by the end of 2021, more PD-1 inhibitors and indications will be included in the medical insurance, and the availability of drugs for the treatment of advanced first-line NSCLC has been further improved.
Reduce patient burden
.
Unique - Immunotherapy reshapes the new pattern of first-line treatment of advanced liver cancer Moderator: Professor Zhou Jian, Zhongshan Hospital Affiliated to Fudan University Speaker: Professor Sun Huichuan, Zhongshan Hospital Affiliated to Fudan University Although TKIs are effective, the survival benefit is limited and a breakthrough is urgently needed
.
Compared with sorafenib alone, immunotherapy such as sintilimab + bevacizumab (double-dose regimen) in the first-line treatment of liver cancer significantly reduced the risk of death by 43% and the risk of disease progression by 44%.
The survival benefit of patients is significant, and the Meta-analysis shows that the combination of Shuangda may become the best clinical solution for the first-line treatment of advanced liver cancer
.
The first-line treatment of liver cancer with Shuangda regimen has obtained the 2022 edition of the National Health Commission's "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer", the 2021 edition of "CSCO Guidelines for Clinical Application of Immune Checkpoint Inhibitors", and the 2021 edition of CACA's "Expert Consensus on Multidisciplinary Comprehensive Treatment of Liver Cancer in China", etc.
The authoritative guide unanimously recommends
.
In addition, phase III clinical studies of first-line treatment based on immunotherapy are in full swing, such as sintilimab combined with anti-CTLA-4 monoclonal antibody (IBI310).
Treatment options, reshape the new pattern of first-line treatment of advanced liver cancer, and bring more benefits to patients
.
Professor Zhou Jian, Professor Sun Huichuan, China-Immunotherapy opens a new chapter in the first-line treatment of advanced gastric cancer Moderator: Professor Li Jin, Dongfang Hospital Affiliated to Tongji University Speaker: Professor Dai Guanghai, General Hospital of the Chinese People's Liberation Army , the prognosis is poor, chemotherapy as a standard treatment has faced a bottleneck in efficacy, and targeted therapy can benefit a limited population, and the current status of advanced gastric cancer treatment is not optimistic
.
The emergence of immunotherapy has brought new hope to patients with gastric cancer.
Several studies have confirmed that immunotherapy has brought benefits to patients with advanced gastric cancer, making it recommended by guidelines
.
Immunotherapy and chemotherapy have a synergistic effect, and combined therapy has repeatedly achieved good results in the exploration of advanced metastatic gastric cancer, breaking the pattern of traditional treatment
.
ORIENT-16 is the first phase III clinical study in China to demonstrate that first-line immunotherapy significantly prolongs the overall survival of patients with advanced gastric cancer.
This study provides strong evidence for the combination of immunotherapy and chemotherapy for advanced gastric cancer in China, and also provides clinical evidence for the combination of sintilimab and chemotherapy.
This first-line treatment option
.
In conclusion, immunotherapy for advanced gastric cancer can be expected in the future, and the combination of biomarker-oriented and immunotherapy will further prolong the OS of patients and promote the development of personalized immunotherapy for gastric cancer
.
Prof.
Li Jin, Prof.
Dai Guanghai Chapter 2: Talking about the truth and sharing the future irAE management experience Moderator: Prof.
Liang Jun, Peking University International Hospital Speaker: Prof.
Zhang Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital ) has a wide spectrum of toxicity, but the overall incidence is low.
Grade 3-4 irAEs are rare, and the occurrence of irAEs is time-regular and reversible
.
In the process of immunotherapy, the diagnosis of irAE is more based on experience and requires the joint participation of a multidisciplinary team to achieve early diagnosis and early treatment
.
It is worth noting that irAEs may occur repeatedly and late, so during the entire immunotherapy process and subsequent follow-up, clinicians should remain vigilant about irAEs and make careful assessments
.
Professor Liang Jun, Professor Zhang Dajia Talks: Current Situation and Prospects of Standardized Diagnosis and Treatment of Tumor Immunity Moderator: Professor Qin Shukui, Nanjing Jinling Hospital Guest: Professor Xu Ruihua, Sun Yat-sen University Cancer Center Four experts from the General Hospital, Professor Hu Yi, shared their insights from different latitudes of standardized diagnosis and treatment of tumor immunity, and made a prospect of the training program to improve the ability of standardized diagnosis and treatment of tumor immunity in "Tumor Immunity Trust China"
.
Experts pointed out that despite the development of science and technology, the survival rate of cancer patients has been continuously improved
.
However, China has a vast territory and abundant resources, and the level of diagnosis and treatment varies among different regions and hospitals
.
At present, the country is vigorously promoting the implementation of the hierarchical diagnosis and treatment policy, which has achieved initial results, and we are also pursuing the maximum development under the policy advantages
.
Through the implementation of training programs such as "Tumor Immunity Xinhuo China" standardized diagnosis and treatment capacity improvement training programs for tumors, higher-level hospitals and primary hospitals can be linked, so as to formulate appropriate treatment strategies for patients in primary hospitals, so that more patients in primary hospitals can achieve "tumor immunity".
chronic disease"
.
Da Jia Tan: The current situation and prospect of standardized diagnosis and treatment of tumor immunity The conference concluded at the end of the conference.
Professor Qin Shukui said in his summary that the conference presented a wonderful academic feast in the form of online live broadcast, and successfully completed the various This agenda has witnessed the launch of the "Tumor Immunity Trust China" training program to improve the standardized diagnosis and treatment capabilities of tumor immunity
.
Sincere thanks to all the academic sharing experts and the behind-the-scenes workers, who have given us a better understanding of the standardized treatment of tumor immunity, and can better guide the immunotherapy drugs for oncology specialists in small and medium-sized cities
.
In the future, I hope that everyone will work together to create a bright future for China's tumor immunotherapy
.
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform
